Annovis Bio, Inc. (ANVS)
After hours:
| Previous close | 11.88 |
| Open | 11.99 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's range | 11.98 - 13.65 |
| 52-week range | 5.42 - 22.49 |
| Volume | |
| Avg. volume | 228,085 |
| Market cap | 140.284M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results. Fourth Quarter 2023 Highlights Clinical Updates Announced Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease (PD) On December 5, 2023, the Company
- GlobeNewswire
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
Further look at earlier Phase 1b study by ADCS unveils confirmatory data MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced the publication of new data from an earlier study supporting buntanetap as a translational inhibitor of amyloid precursor protein (APP) in patients with early Alzheimer’s Disease (AD). Buntanetap is an oral molecule that selectively
- GlobeNewswire
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease (AD). Topline efficacy data is expected in April. "We are excited to share that we now move from data cleaning to organization and statistical evaluation of data for our A
